Newsroom | 91611 results

LOS ANGELES--(BUSINESS WIRE)--Fifty Countries Strong: AHF ‘Keeping the Promise’ on World AIDS Day...

DUBLIN--(BUSINESS WIRE)--The "Rimiterol (CAS 32953-89-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Rimiterol provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understa...

DUBLIN--(BUSINESS WIRE)--The "Mepixanox (CAS 17854-59-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Mepixanox provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understa...

DUBLIN--(BUSINESS WIRE)--The "Sertraline (CAS 79617-96-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Sertraline provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for unders...

DUBLIN--(BUSINESS WIRE)--The "A Practical Guide to Producing and Maintaining the PSMF Training Course (Feb 13, 2026)" training has been added to ResearchAndMarkets.com's offering. This course will provide a practical guide to planning, writing, maintaining and updating the PSMF to ensure compliance. The pharmacovigilance system master file (PSMF) is a legal requirement for any medicinal product authorised in the European Union. The PSMF provides the regulators with a detailed description and as...

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of November 27, 2025...

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.1 “Today’s approval lays a solid foundation for Celltrion’s expansion into the Canadian ophthalmology market and represents a significant milestone in diversifying the company’s portfolio,” said Jungyong Shin, Managing Director at Celltrion...

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. annoncé aujourd'hui que Santé Canada a approuvé l'Eydenzelt®, un biosimilaire référençant l'Eylea® (aflibercept 2mg), en flacon et en seringue préremplie, pour le traitement de toutes les indications approuvées pour l'Eylea.1 « L’approbation d’aujourd’hui jette des bases solides pour l’expansion de Celltrion sur le marché canadien de l’ophtalmologie et représente une étape importante dans la diversification du portefeuille de la société », décl...

LOS ANGELES--(BUSINESS WIRE)--Une nouvelle lettre publiée dans The Lancet HIV et envoyée par la AIDS Healthcare Foundation (AHF) soulève des inquiétudes quant au fait que le système à trois tests de dépistage du VIH recommandé par l’Organisation mondiale de la Santé pour éviter les rares résultats faussement positifs, pourrait involontairement ralentir la mise en place rapide des traitements vitaux contre le VIH. Bien que cette stratégie vise à améliorer la précision, de nombreuses cliniques ma...

LOS ANGELES--(BUSINESS WIRE)--In einem aktuellen Leserbrief der AIDS Healthcare Foundation (AHF) in The Lancet HIV wird die Befürchtung geäußert, dass das von der Weltgesundheitsorganisation empfohlene Drei-Test-System zur HIV-Diagnose — das entwickelt wurde, um seltene falsch-positive Ergebnisse zu vermeiden — unbeabsichtigt den Beginn einer lebensrettenden HIV-Behandlung verzögern könnte. Das Ziel dieser Strategie ist zwar eine höhere Genauigkeit, aber vielen Kliniken fehlt es an Personal, Ma...